Laboratory characterization of obligate carriers of type 3 von Willebrand disease with a potential role for Platelet Function Analyzer (PFA-200)

被引:2
作者
Geevar, Tulasi [1 ]
Dave, Rutvi Gautam [1 ]
Mathews, Nitty Skariah [1 ]
Kumar, Snehil [1 ]
Mammen, Joy John [1 ]
Vijayan, Ramya [1 ]
Aboobacker, Fouzia N. [2 ]
Abraham, Aby [2 ]
Srivastava, Alok [2 ]
Nair, Sukesh Chandran [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Transfus Med & Immunohematol, Vellore 632004, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Dept Clin Hematol, Vellore, Tamil Nadu, India
关键词
carrier; PFA-100; 200; Type 3 von Willebrand disease; von Willebrand disease; von Willebrand factor; HETEROZYGOUS CARRIERS; HEMORRHAGIC SYMPTOMS; FACTOR DEFICIENCY; CLINICAL UTILITY; BLEEDING HISTORY; BLOOD-GROUP; DIAGNOSIS; MANAGEMENT; RISK; ABO;
D O I
10.1111/ijlh.13787
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Type 3 von Willebrand disease (VWD) is a rare autosomal recessive disorder characterized by undetectable von Willebrand Antigen (VWF:Ag). Carriers of type 3 VWD carry one null allele and have von Willebrand factor (VWF) at about 50% of normal. The aim of this study was to characterize type 3 VWD carriers and to study the role of Platelet Function Analyzer (PFA-200) in this cohort. Methods This was a cross-sectional study where data were collected from carriers (parents/offspring) of type 3 VWD patients and evaluated with activated partial thromboplastin time, factor VIII, blood group, ristocetin cofactor assay (VWF:RCo), VWF:Ag, and closure time on PFA-200 with collagen/epinephrine (COL/EPI), and collagen/ADP (COL/ADP). Results One hundred carriers were included in the study of which 85 were included for PFA-200 analysis. The mean (SD) of VWF:Ag (IU/ml) and VWF:RCo (IU/ml) was 0.63 (0.24) and 0.61 (0.26), respectively. Among the 100 carriers, based on VWF levels (VWF:Ag and/or VWF:RCo) and bleeding history, there were 7 type 1 VWD, 10 type 2 VWD, 25 borderline VWF (0.30-0.50 IU/ml and no bleeding), and 58 normal VWF (>0.50 IU/ml). PFA-200 was prolonged in 71% of the carriers, all carriers with type 1 and type 2 VWD phenotype, 80% carriers with borderline VWF, and 59% with normal VWF. COL/EPI was more sensitive than COL/ADP and showed better correlation with VWF parameters than COL/ADP. Conclusion Carriers of type 3 VWD can have a variable laboratory phenotype. PFA-200 showed good sensitivity among the carriers at VWF levels <0.50 IU/ml.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 33 条
  • [21] THE ROLE OF PLATELET VON-WILLEBRAND-FACTOR IN PLATELET-ADHESION AND THROMBUS FORMATION - A STUDY OF 34 PATIENTS WITH VARIOUS SUBTYPES OF TYPE-I VON-WILLEBRAND DISEASE
    FRESSINAUD, E
    FEDERICI, AB
    CASTAMAN, G
    ROTHSCHILD, C
    RODEGHIERO, F
    BAUMGARTNER, HR
    MANNUCCI, PM
    MEYER, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (02) : 327 - 332
  • [22] Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A
    Sood, S. L.
    Cuker, A.
    Wang, C.
    Metjian, A. D.
    Chiang, E. Y.
    Soucie, J. M.
    Konkle, B. A.
    HAEMOPHILIA, 2013, 19 (04) : 595 - 601
  • [23] Platelet morphological changes in 2 patients with von Willebrand disease type 3 caused by large homozygous deletions of the von Willebrand factor gene
    Nurden, Paquita
    Nurden, Alan T.
    La Marca, Silvia
    Punzo, Margherita
    Baronciani, Luciano
    Federici, Augusto B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (11): : 1627 - 1629
  • [24] Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease in southern Iran
    Shamsakhzari, Shoeleh
    Afrasiabi, Abdolreza
    Haghpanah, Sezaneh
    Karimi, Mehran
    BLOOD COAGULATION & FIBRINOLYSIS, 2011, 22 (04) : 325 - 330
  • [25] Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease
    Baronciani, L
    Cozzi, G
    Canciani, MT
    Peyvandi, F
    Srivastava, A
    Federici, AB
    Mannucci, PM
    THROMBOSIS AND HAEMOSTASIS, 2000, 84 (04) : 536 - 540
  • [26] Risk of perinatal intracranial hemorrhage and role of prenatal genetic testing in individuals with type 3 von Willebrand disease
    Warad, Deepti
    Ismail, Maryama
    Rusk, Dawn
    Rodriguez, Vilmarie
    Pruthi, Rajiv K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (10) : 2779 - 2780
  • [27] Phenotypic and genotypic characterization of 10 Finnish patients with von Willebrand disease type 3: discovery of two main mutations
    Jokela, V.
    Lassila, R.
    Szanto, T.
    Joutsi-Korhonen, L.
    Armstrong, E.
    Oyen, F.
    Schneppenheim, S.
    Schneppenheim, R.
    HAEMOPHILIA, 2013, 19 (06) : E344 - E348
  • [28] Laboratory Diagnosis of von Willebrand Disease Type 1/2E (2A Subtype IIE), Type 1 Vicenza and Mild Type 1 Caused by Mutations in the D3, D4, B1-B3 and C1-C2 Domains of the von Willebrand Factor Gene Role of von Willebrand Factor Multimers and the von Willebrand Factor Propeptide/Antigen Ratio
    Gadisseur, Alain
    Berneman, Zwi
    Schroyens, Wilfried
    Michiels, Jan Jacques
    ACTA HAEMATOLOGICA, 2009, 121 (2-3) : 128 - 138
  • [29] A new case of platelet-type von Willebrand disease supports the recent findings of gain-of-function GP1BA variants outside the C-terminal disulphide loop enhances affinity for von Willebrand factor
    Monteiro, Catarina
    Goncalves, Ana
    Pereira, Monica
    Lau, Catarina
    Morais, Sara
    Santos, Rosario
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (04) : 673 - 677
  • [30] Local and systemic effects of intra-arterial desmopressin in healthy volunteers and patients with type 3 von Willebrand disease - Role of interleukin-6
    Newby, DE
    Stewart, A
    Witherow, FN
    Grieve, S
    Dawson, P
    Fox, KAA
    Webb, DJ
    Ludlam, CA
    THROMBOSIS AND HAEMOSTASIS, 2000, 84 (02) : 195 - 203